摘要
ⅢA-N2期非小细胞肺癌(NSCLC)是一组异质性较大的疾病,最佳治疗模式仍存在争议。如何将化疗、放疗、靶向及免疫治疗等多种治疗手段合理的应用于这部分患者的新辅助治疗中,目前尚无定论。本文就NSCLC新辅助治疗相关研究进行综述,对不同新辅助治疗模式进行疗效及安全性方面的评估。
ⅢA-N2 NSCLC is a group of heterogeneous diseases.The optimal treatment modality remains controversial.How to choose suitable neoadjuvant treatment modalities including chemotherapy,radiotherapy,target therapy and immunotherapy remains unclear.In this article,research progress on neoadjuvant therapy of NSCLC was reviewed to evaluate the efficacy and safety for different modalities.
作者
孙鑫
门玉
惠周光
Sun Xin;Men Yu;Hui Zhouguang(Department of Radiation Oncology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences(CAMS)and Peking Union Medical College(PUMC),Beijing 100021,China;Department of VIP Medical Services,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences(CAMS)and Peking Union Medical College(PUMC),Beijing 100021,China)
出处
《中华放射肿瘤学杂志》
CSCD
北大核心
2020年第1期61-64,共4页
Chinese Journal of Radiation Oncology
关键词
癌
非小细胞肺/新辅助治疗
研究进展
Carcinoma
non-small cell lung/neoadjuvant therapy
Research progress
